RAS signaling is a key driver of many cancers
RAS signaling is a key driver of many cancers. KRAS and other RAS genes are often mutated to hyperactivate the RAS protein and downstream pathways in patient tumors. Targeted therapies are needed to block these tumor signaling networks that lead to cancer progression. Oral drugs that target KRAS, NRAS, and HRAS signaling pathways are vital both at the intiation of therapy and where patients may become resistant to prior therapies.
RAS hub discovery:
Key residues in the KRAS oncoprotein (KRASG12D, KRASG12V, KRASG12C, and other KRAS and NRAS mutations) are mutated in cancers, at nearly 250,000 new cases and one-quarter of all cases in the U.S. alone.
Key residues in the KRAS oncoprotein (KRASG12D, KRASG12V, KRASG12C, and other KRAS and NRAS mutations) are mutated in cancers, at nearly 250,000 new cases and one-quarter of all cases in the U.S. alone.
Our clinical trials:
280Bio is conducting several ongoing clinical trials for patients with RAS mutations. Please review our clinical trials page to learn more.
News
